Stay updated with breaking news from Small Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The psychedelic drug market is on the brink of extraordinary growth, projected to soar to $7.2 billion by 2029, reflecting a robust 55 per cent compound annual growth rate (CAGR), according to a report on Monday.This ascent is propelled by ...
Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD.)
Cybin Inc. (NYSE-A:CYBN, NEO:CYBN) shares maintained upward momentum on Wednesday after soaring earlier this week on the news New York Mets owner Steve...
Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN).
Visiongain has published a new report entitled Contract Research Organisations (CROs) Market Report 2023-2033: Forecasts by Service (Preclinical, Clinical, Laboratory Services, Consulting Services, Data Management